Comparative Analysis of the Vertical Risk of Transmission of Some Blood-Borne Infections in the Republic of Guinea

The aim of our work was to compare the HBV, HCV and HIV vertical transmission risk in the Republic of Guinea.

Materials and methods. The material for the study was 305 blood plasma samples from pregnant women living in Conakry, Republic of Guinea. The samples were examined for the presence of serological (HBsAg, antibodies antiHBs IgG, anti-HBcore IgG, anti-HCV IgG, Ag/Ab-HIV) and molecular (HBV DNA, HCV RNA, HIV RNA) markers.

Results and discussion. When assessing the overall prevalence of serological markers among patients, the incidence of HBV markers was 76.06 %. Antibodies to HCV were detected only in 1 case, which amounted to 0.32 %. HIV markers were detected in 3 cases, which amounted to 0.98 %. The prevalence of HBsAg in the group under examination significantly differed between the groups of pregnant women aged 13–19 years (17.33 %) and 20–24 years (12.12 %), p<0.0001, RR=5.107 with 95 % CI: 2.458–10.612. When assessing the overall prevalence of molecular-biological markers among patients, we did not detect HIV RNA, in one patient, HCV RNA was determined, which was 0.32 %, while the incidence of HBV DNA was 20 %. Among HBsAg-positive individuals, HBV DNA was detected in 86.11 %, which was 10.16 % of the total group. Among the HBsAg-negative individuals, HBV DNA was detected in 11.15 % (9.84 % of the total group). It should be noted that in nine cases, HBV DNA was detected without any serological markers, which amounted to 14.75 % (2.95 % of the total group). Assessment of the blood-borne infections prevalence in pregnant women is significant for the subsequent identification of pathogen transmission routes in order to control and/or prevent the spread of infection.

1. World Health Organization. Hepatitis B. Key facts. 2020. (Cited: December 26, 2020). [Internet]. Available from: http://www. who.int/news-room/fact-sheets/detail/hepatitis-b.

2. World Health Organization. Hepatitis C. Key facts. 2020. (Cited: December 26, 2020). [Internet]. Available from: http://www.who.int/news-room/fact-sheets/detail/hepatitis-c.

3. CDC: How viral hepatitis impacts millions of people worldwide. (Cited: December 26, 2020). [Internet]. Available from: https://www.cdc.gov/hepatitis/awareness/worldhepday.htm.

4. UNAIDS. Global HIV and AIDS statistics-2020 fact sheet (Online) 2020. (Cited: December 10, 2020). [Internet]. Available from: http://www.unaids.org/en/resources/fact-sheet/.

5. UNAIDS. UNAIDS strategy development (Online) 2020. (Cited: December 10, 2020). [Internet]. Available from: https://www. unaids.org/en/Global_AIDS_strategy/.

6. Raizada A., Dwivedi S., Bhattacharya S. Hepatitis B, hepatitis C and HIV co-infection at an antiretroviral centre in Delhi. Trop. Doct. 2011; 41(3):154–6. DOI: 10.1258/td.2011.100440.

7. Tse K.Y., Ho L.F., Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J. Hepatol. 2005; 43(5):771–5. DOI: 10.1016/j.jhep.2005.05.023.

8. Dafallah S.E., El-Agib F.H., Bushra G.O. Maternal mortality in a teaching hospital in Sudan. Saudi Med. J. 2003; 24(4):369–72.

9. Cui A.M., Cheng X.Y., Shao J.G., Li H.B., Wang X.L., Shen Y., Mao L.J., Zhang S., Liu H.Y., Zhang L., Qin G. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. BMC Pregnancy and Childbirth. 2016; 16:87. DOI: 10.1186/s12884-016-0884-1.

10. Deressa T., Damtie D., Fonseca K., Gao S., Abate E., Alemu S., Aleka Y., Swain M.G., van Marle G., Coffin C.S. The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia. PLoS One. 2017; 12(12):e0190149. DOI: 10.1371/journal.pone.0190149.

11. [Population of Guinea. Countrymeters]. (Cited: March 04, 2021). [Internet]. Available from: http://countrymeters.info/ru/guinea.

12. [Republic of Guinea]. (Cited: December 20, 2020). [Internet]. Available from: https://gtmarket.ru/countries/guinea.

13. Naydenova E.V., Lopatin A.A., Safronov V.A., Kolomoets E.V., Levkovsky A.E., Silla A.L., Starshinov V.A., Shcherbakova S.A., Maleev V.V. [Ensuring biological safety when carrying out anti-epidemic measures during the elimination of the Ebola epidemic in the Republic of Guinea]. Infektsionnye Bolezni: Novosti, Mneniya, Obuchenie. [Infectious Diseases: News, Opinions, Training]. 2018; 7(3):102–8. DOI: 10.24411/2305-3496-2018-13015.

14. Annuaire Statistique 2019. (Cited: December 20, 2020). [Internet]. Available from: http://www.stat-guinee.org.

15. Camara B.S., Delamou A., Diro E., Béavogui A.H., El Ayadi A.M., Sidibé S., Grovogui F.M., Takarinda K.C., Bouedouno P., Sandouno S.D., Okumura J., Baldé M.D., Van Griensven J., Zachariah R. Effect of the 2014/2015 Ebola outbreak on reproductive health services in a rural district of Guinea: an ecological study. Trans. R. Soc. Trop. Med. Hyg. 2017; 111(1):22–9. DOI: 10.1093/trstmh/trx009.

16. Leno N.N., Delamou A., Koita Y., Diallo T.S., Kaba A., Delvaux T., Van Damme W., Laga M. Ebola virus disease outbreak in Guinea: what effects on prevention of mother-to-child transmission of HIV services? Reprod. Health. 2018; 15(1):60. DOI: 10.1186/s12978-018-0502-y.

17. Ostankova Yu.V., Semenov A.V., Totolyan A.A. [Detection of hepatitis B virus in blood plasma at low viral load]. Klinicheskaya Laboratornaya Diagnostika. [Clinical Laboratory Diagnostics]. 2019. 64(10):635–40. DOI: 10.18821/0869-2084-2019-64-10-635-640.

18. Adolescent pregnancy. 31.01.2020. (Cited: December 20, 2020). [Internet]. Available from: https://www.who.int/en/newsroom/fact-sheets/detail/adolescent-pregnancy.

19. Zampino R., Boemio A., Sagnelli C., Alessio L., Adinolfi L.E., Sagnelli E., Coppola N. Hepatitis B virus burden in developing countries. World J. Gastroenterol. 2015; 21(42):11941–53. DOI: 10.3748/wjg.v21.i42.11941.

20. Wang C.C., Cheng P.N., Kao J.H. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment. Pharmacol. Ther. 2020; 51(2):216–30. DOI: 10.1111/apt.15575.

21. Domínguez-Rodríguez S., Prieto L., Fernández McPhee C., Illán-Ramos M., Beceiro J., Escosa L., Muñoz E., Olabarrieta I., Regidor F.J., Roa M.Á., Viñuela Beneítez M.D.C., Guillén S., Navarro-Gómez M.L., Ramos Amador J.T. Perinatal HCV transmission rate in HIV/HCV co-infected women with access to ART in Madrid, Spain. PLoS One. 2020; 15(4):e0230109. DOI: 10.1371/journal.pone.0230109.

22. Popova A.Yu., Kutyrev V.V., editors. [Russia – Guinea: Results and Prospects of Cooperation in the Field of Ensuring the Sanitary and Epidemiological Welfare of the Population]. Saratov: “Amirit”; 2020. 272 p.

23. Mora N., Adams W.H., Kliethermes S., Dugas L., Balasubramanian N., Sandhu J., Nde H., Small C., Jose J., Scaglione S., Layden J.E. A synthesis of hepatitis C prevalence estimates in sub-Saharan Africa: 2000–2013. BMC Infect. Dis. 2016; 16:283. DOI: 10.1186/s12879-016-1584-1.

24. Ofori-Asenso R., Agyeman A.A. Hepatitis B in Ghana: a systematic review & meta-analysis of prevalence studies (1995–2015). BMC Infect. Dis. 2016; 16:130. DOI: 10.1186/s12879-016-1467-5.

25. Sonderup M.W., Afihene M., Ally R., Apica B., Awuku Y., Cunha L., Dusheiko G., Gogela N., Lohouès-Kouacou M.J., Lam P., Lesi O., Mbaye P.S., Musabeyezu E., Musau B., Ojo O., Rwegasha J., Scholz B., Shewaye A.B., Tzeuton C., Kassianides C., Spearman C.W. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. Lancet Gastroenterol. Hepatol. 2017; 2(12):910–9. DOI: 10.1016/S24681253(17)30249-2.

26. Kaba D., Bangoura M.A., Sylla M.M., Sako F.B., Diallo M.S., Diallo I., Kolié O.Y., Keita A.S., Diané B.F., Keita F., Diakité M., Kanté M.D., Savané M., Sylla D., Kaké A., Diallo K., Touré M., Cissé M. Prevalence and factors associated with hepatitis B in a cohort of HIV-infected children in the Pediatric Department at Donka National Hospital, Guinea. Pan Afr. Med. J. 2019; 34:182. DOI: 10.11604/pamj.2019.34.182.16275.

27. Frempong M.T., Ntiamoah P., Annani-Akollor M.E., Owiredu W.K.B.A., Addai-Mensah O., Owiredu E.W., Adu-Gyasi D., Agyapong E.O., Sallah L. Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana. PLoS One. 2019; 14(7):e0219922. DOI: 10.1371/journal. pone.0219922.

28. Olayinka A.T., Oyemakinde A., Balogun M.S., Ajudua A., Nguku P., Aderinola M., Egwuenu-Oladejo A., Ajisegiri S.W., Sha’aibu S., Musa B.O., Gidado S., Nasidi A. Seroprevalence of hepatitis B infection in Nigeria: a national survey. Am. J. Trop. Med. Hyg. 2016; 95(4):902–7. DOI: 10.4269/ajtmh.15-0874.

29. Opaleye O.O., Igboama M.C., Ojo J.A., Odewale G. Seroprevalence of HIV, HBV, and HCV and HTLV among pregnant women in Southwestern Nigeria. J. Immunoassay Immunochem. 2016; 37(1):29–42. DOI: 10.1080/15321819.2015.1040160.

30. Bittaye M., Idoko P., Ekele B.A., Obed S.A., Nyan O. Hepatitis B virus sero-prevalence amongst pregnant women in the Gambia. BMC Infect. Dis. 2019. 19(1):259–67. DOI: 10.1186/s12879-019-3883-9.

31. Rouet F., Chaix M.L., Inwoley A., Msellati P., Viho I., Combe P., Leroy V., Dabis F., Rouzioux C. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d’Ivoire: the ANRS 1236 study. J. Med. Virol. 2004; 74(1):34–40. DOI: 10.1002/jmv.20143.

32. MacLean B., Hess R.F., Bonvillain E., Kamate J., Dao D., Cosimano A., Hoy S. Seroprevalence of hepatitis B surface antigen among pregnant women attending the Hospital for Women & Children in Koutiala, Mali. S. Afr. Med. J. 2011; 102(1):47–9.

33. Bouare N., Vaira D., Gothot A., Delwaide J., Bontems S., Seidel L., Gerard P., Gerard C. Prevalence of HIV and HCV infections in two populations of Malian women and serological assays performances. World J. Hepatol. 2012; 4(12):365–73. DOI: 10.4254/wjh.v4.i12.365.

34. Hønge B.L., Olesen J.S., Jensen M.M., Jespersen S., da Silva Z.J., Rodrigues A., Laursen A.L., Wejse C., Krarup H., Aaby P., Erikstrup C. Hepatitis B and C in the adult population of Bissau, Guinea-Bissau: a cross-sectional survey. Trop. Med. Int. Health. 2020; 25(2):255–63. DOI: 10.1111/tmi.13335.

35. Bordeaux Call 2018 for the Fight against Viral Hepatitis B and C. (Cited: December 20, 2020). [Internet]. Available from: http://www.afravih2018.org/appel-de-bordeaux.

36. Kwadzokpui P.K., Akorsu E.E., Abaka-Yawson A., Quarshie S.S., Amankwah S.A., Tawiah P.A. Prevalence and knowledge of hepatitis B virus infection among pregnant women in the NingoPrampram District, Ghana. Int. J. Hepatol. 2020; 2020:7965146. DOI: 10.1155/2020/7965146.

37. Graber-Stiehl I. The silent epidemic killing more people than HIV, malaria or TB. Nature. 2018; 564:24–6. DOI: 10.1038/d41586-018-07592-7.

38. Importance of hepatitis elimination and hepatitis B vaccination. Remarks of WHO Regional Director for Africa at the Highlevel Global Talk Show: Towards a “Hepatitis-free future”. (Cited: December 20, 2020). [Internet]. Available from: https://www.afro.who.int/regional-director/speeches-messages/importance-hepatitiselimination-and-hepatitis-b-vaccination#_ftn1.